Association Between Lipoprotein A Levels and Vulnerable Atherosclerotic Plaques.

Arankesh Mahadevan¹, Himanshu S Jog², Hemanth Dhananjaya³, Mansi Patel⁴, Mehak Preet Singh Marwah⁵, Murtaza H Gandhi⁶, Srivatsa Surya Vasudevan⁷, Sai Prasanna Lekkala⁸, Hajra K Mehdi⁹, Rupak Desai¹⁰

¹University of Utah Health, Salt Lake City, Utah, USA.

²M.S Ramaiah Medical College, Bangalore, India. Electronic address: joghimanshu@gmail.com.

³M.S Ramaiah Medical College, Bangalore, India.

⁴Government Medical College, Surat, India.

⁵Guru Gobind Singh Medical College, Faridkot, India.

⁶Terna Medical College, Navi Mumbai, India.

⁷Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.

⁸UC Health Parkview Medical Center, Pueblo, Colorado, USA.

⁹Optum Ballard, Seattle, Washington, USA.

¹⁰Independent Outcomes Researcher, Atlanta, USA.

PubMed DOI

Abstract

BACKGROUND: Elevated lipoprotein(a) [Lp(a)] is an established cardiovascular risk factor, but its association with imaging-defined vulnerable plaque features remains incompletely characterized. METHODS: We systematically searched PubMed, Scopus, and Embase for observational studies comparing elevated versus lower Lp(a) levels and reporting thin-cap fibroatheroma (TCFA) or lipid-rich plaques. Rand…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.